



The new world of RNAs

Danyella Barbosa Dogini¹, Vinícius D'Avila Bittencourt Pascoal², Simoni Helena Avansini¹, André Schwambach Vieira¹, Tiago Campos Pereira³ and Iscia Lopes-Cendes¹

¹*Departamento de Genética Médica, Faculdade de Ciências Médicas, Universidade Estadual de Campinas, Campinas, SP, Brazil.*

²*Faculdade de Ciências Básicas, Universidade Federal Fluminense, Nova Friburgo, RJ, Brazil.*

³*Departamento de Biologia, Faculdade de Filosofia Ciências e Letras de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brazil.*

Abstract

One of the major developments that resulted from the human genome sequencing projects was a better understanding of the role of non-coding RNAs (ncRNAs). ncRNAs are divided into several different categories according to size and function; however, one shared feature is that they are not translated into proteins. In this review, we will discuss relevant aspects of ncRNAs, focusing on two main types: i) microRNAs, which negatively regulate gene expression either by translational repression or target mRNA degradation, and ii) small interfering RNAs (siRNAs), which are involved in the biological process of RNA interference (RNAi). Our knowledge regarding these two types of ncRNAs has increased dramatically over the past decade, and they have a great potential to become therapeutic alternatives for a variety of human conditions.

Keywords: non-coding RNAs, microRNAs, RNA interference, RNA-based drugs.

Introduction

One of the main goals of the *Human Genome Project* was to identify all human genes (Collins *et al.*, 1998). It was estimated that the human genome contained approximately 100,000-150,000 genes. However, only nearly 20,000 genes could be identified at the end of the project; therefore, protein-coding sequences represent only 1.5% of the human genome. The rest of the genome, approximately 98%, was considered junk DNA because it is composed of sequences that are not translated into proteins. These sequences were believed to be mainly part of regulatory regions or non-coding regions that did not play an important role in cell function (Lander *et al.*, 2001). These conclusions were based on the central dogma of molecular biology (Crick, 1958), which considers that all relevant information contained in the DNA will be transcribed into messenger RNA (mRNA) molecules that will be subsequently translated into proteins, which are the important molecular players in cell function (including the regulation of gene expression). The concept of two main classes of RNA molecules already existed: i) RNAs which were translated into proteins, *i.e.*, mRNAs, and ii) the group of non-coding RNAs (ncRNAs), mainly comprising transfer

RNAs (tRNAs) and ribosomal RNAs (rRNAs). However, as additional studies were performed, it became clear that ncRNAs were much more abundant than expected, and they were present in several different organisms, with a particularly high abundance in *Homo sapiens* (Hüttenhofer *et al.*, 2005). These findings prompted the development of a new specific field in molecular biology, the study of ncRNAs, which has become increasingly relevant in the past decade. As knowledge advances, it becomes clear that discoveries in the field of ncRNAs are likely to make significant contributions to the biomedical sciences, including the possibility of novel therapeutic alternatives for a variety of human conditions.

Non-coding RNAs

The length of ncRNAs can vary from 21 to several thousand nucleotides (nt) and these molecules are divided into i) long or large RNAs, such as transfer RNA, ribosomal RNA and X-inactive specific transcript RNA (XIST RNA), and ii) small ncRNAs, such as microRNAs (miRNAs), small interfering RNAs (siRNAs), repeat associated small interfering RNAs (rasiRNAs), small nucleolar RNAs (snoRNAs), small nuclear RNAs (snRNAs), piwi-interacting RNAs (piRNAs) and others (Gavazzo *et al.*, 2013). Table 1 summarizes the different types of ncRNAs described, as well as some of their main characteristics.

Table 1 - Different types, main characteristics and functions of non-coding RNAs.

		Mean size	Function
Long ncRNA	Ribosomal RNA	~1.9 kb	Essential for protein synthesis
	XIST RNA	~17 kb	Chromosome X inactivation
	Other lncRNA	> 200 nt	Involved in epigenetic modification, post-transcriptional processing, modulation of chromatin structure, etc.
Small ncRNA	miRNAs	18-21 nt	Gene regulation
	siRNA	~21 nt	Gene regulation; defense against viruses and transposon activity
	rasiRNA	24-27 nt	Orientation of heterochromatin in the formation of centromeres
	snoRNA	60-300 nt	Methylation and pseudo uridylation of other RNAs
	snRNA	100-300 nt	Involved in spliceosome complex
	piRNA	26-30 nt	Regulation of transposon activity and chromatin state

siRNAs are approximately 21 nt in length and are produced from the processing of double-stranded RNA molecules by the enzyme Dicer. siRNAs are involved in gene regulation, as well as viral defense and transposon activity (Ghildiyal and Zamore, 2009; Malone and Hannon, 2009). rasiRNAs are approximately 24-27 nt long and play a role in heterochromatin orientation during the formation of centromeres (Theurkauf *et al.*, 2006; Josse *et al.*, 2007). snoRNAs consist of approximately 80 nt and are believed to be involved in the guidance of uridylation and/or site-specific methylation during ribosomal RNA maturation (Dieci *et al.*, 2009; Taft *et al.*, 2009); in addition, there is evidence that snoRNAs can also play a role in the regulation of gene expression (Matera *et al.*, 2007). snRNAs have been shown to be part of the spliceosome complex (Peters and Robson, 2008; Tazi *et al.*, 2009) and are important for removing introns from immature mRNAs (Valadkhan, 2005). piRNAs are approximately 26 to 30 nt in length, are restricted to germ line cells and function with AGO and PIWI proteins to regulate transposon activity and chromatin states (Ghildiyal and Zamore, 2009; Malone and Hannon, 2009). PiRNAs are also highly expressed in mammalian cells at the pachytene stage (Megosh *et al.*, 2006).

Next, we will present additional information about miRNAs and siRNAs, because these are better characterized in terms of their functions and their impact in human health and disease.

microRNAs

MicroRNAs (miRNAs) are small endogenous ncRNAs that regulate gene expression post-transcriptionally in a sequence-specific manner (Bartel, 2004). In 1993, Victor Ambros and colleagues observed a mutant strain of *Caenorhabditis elegans* that exhibited developmental abnormalities, such as the inability to form the vulva (Lee *et al.*, 1993). These authors observed that the gene responsible for these phenotypes, *lin-4*, had two transcripts: one, which was more abundant and 61 nt in length and a second 21 nt transcript that was not translated. *lin-14* was shown to encode a nuclear protein that participates in the

regulation of the transition from the first (L1) to the second (L2) larval stages in *C. elegans* (Ruvkun and Giusto, 1989; Lee *et al.*, 1993). Subsequent studies revealed that the 21 nt transcript is complementary to the 3' untranslated region (3'UTR) of *lin-14* and, most interestingly, negatively regulates the expression of *lin-14* (Lee *et al.*, 1993). Initially, these findings were not adequately appreciated by the scientific community, because it was believed to be a rare process occurring only in *C. elegans*. However, in 2000, another such 22 nt non-coding RNA, *let-7*, was identified in *C. elegans* (Reinhart *et al.*, 2000). Surprisingly, it was also found to be complementary to the 3'UTR of another gene, *lin-41*, promoting its translational knockdown. In addition, the *let-7* sequence was shown to be highly conserved in most organisms, including non-nematodes (Pasquinelli *et al.*, 2000). These findings officially started a new field of investigation in small ncRNAs, more specifically, miRNAs. Currently, the existence of miRNAs has been extensively shown in insects and mammals (Ambros, 2001; Ambros *et al.*, 2003; Lagos-Quintana *et al.*, 2003; Mattick and Makunin, 2005), and the database of miRNAs has registered approximately 25,000 sequences found in 32 organisms representing vertebrates, invertebrates, plants and viruses (<http://www.mirbase.org/>).

miRNA biogenesis

Most miRNAs described to date are transcribed from sequences present in intergenic regions (Lagos-Quintana *et al.*, 2001; Lau *et al.*, 2001), but 25% of human miRNAs identified are located in intronic regions and are transcribed in the same direction as the pre-messenger RNA, leading to the hypothesis that these miRNAs may use the promoter region of mRNAs for their transcription (Aravin *et al.*, 2003; Lai *et al.*, 2003).

miRNAs are transcribed by RNA polymerase II from what are called MIR genes. The first intermediate transcripts are 'hairpin' molecules called pri-miR. Similar to mRNAs, these transcripts undergo capping and polyadenylation at the 5' and 3' ends of the transcript, respectively (Lee *et al.*, 2002; Cai *et al.*, 2004; Kim, 2005).

Unlike mRNAs, miRNA maturation begins in the nucleus and finishes in the cytoplasm. In animals, the nuclear processing is performed by DROSHA, an RNase type III enzyme with endonucleolytic activity, which, in combination with PASHA (Lee *et al.*, 2003), recognizes the 'hairpin' structure of the pri-miR and cleaves it. This generates a pre-miR of approximately 60-70 nt in length. Pre-miRs are transported to the cytoplasm by exportin-5 and the cofactor Ran-GTP (Yi *et al.*, 2003; Lund *et al.*, 2004; Shibata *et al.*, 2006). Once in the cytoplasm, pre-miRs are processed by the enzyme DICER, thus generating dimeric miRNA:miRNA* molecules approximately 22 nt in length (Hutvagner *et al.*, 2001). Whereas mammals typically encode a single DICER that can generate several classes of small RNAs, *Drosophila* and *C. elegans* have two types of Dicer (Lee *et al.*, 2004). Plants require multiple types of Dicers; four and six different classes of DICER-like (DCL) enzymes have been identified in *Arabidopsis thaliana* and rice, respectively. In *Arabidopsis*, DCL 2, 3 and 4 are involved in the formation of different species of siRNAs, whereas DCL 1 is exclusively responsible for the biogenesis of miRNAs (Bernstein *et al.*, 2001). In addition, it has been demonstrated that each Dicer produces siRNAs with specific sizes: DCL2, DCL4 and DCL3 form siRNAs with 22, 24 and 21 nt, respectively (Xie *et al.*, 2005; Deleris *et al.*, 2006; Blevins *et al.*, 2006). The cleavage performed by DICER and Drosha will ultimately define the dimer miRNA:miRNA* extremity; the strand with a lower free energy at the 5' end is incorporated by RISC (RNA-induced silencing complex), while the other strand is degraded (Khvorova *et al.*, 2003). The miRNA bound to the RISC structure is guided to the complementary sequence of the target mRNA. If the pairing is complete (100% sequence complementarity between the miRNA and mRNA), the mRNA will be degraded; however, if the sequence is only partially complementary, this will result in translational inhibition of the mRNA (Cannell *et al.*, 2008).

One unique aspect of miRNA regulation is its complexity. It has been observed that a single miRNA can regulate expression of different mRNAs. Additionally, one mRNA can be regulated by multiple miRNAs (Yanaihara *et al.*, 2006). In *C. elegans*, the miRNA lin-4 regulates the expression of the lin-14 gene as well as the heterochronic gene lin-28. A homolog of lin-14 exists in animals, and in mouse and human cells, it is regulated by miR-125a and let-7b (Moss and Tang, 2003).

miRNAs can also be produced by an alternative pathway. In this new model, sequences present in introns are capable of being transcribed as miRNAs. This hypothesis is derived from experiments in which an analysis was performed in pooled sequences from *Drosophila* S2 cells, leading to the mapping of miR:miR* duplexes (Ruby *et al.*, 2007). It is believed that nearly 80% of animal miRNAs are transcribed from introns, and these miRNAs are known as mirtrons (; Rodriguez *et al.*, 2004; Kim and Kim, 2007;

Okamura *et al.*, 2007; Ruby *et al.*, 2007). The formation of mirtrons differs from classical miRNA biogenesis because it does not require DROSHA proteins (Han *et al.*, 2006; Kim and Kim, 2007; Wang *et al.*, 2007); instead, mirtrons require AGO1 proteins for maturity (Okamura *et al.*, 2007).

The pathway through which miRNAs regulate mRNA translation involves the mechanism used by cells as a defense against exogenous mRNA (such as in a viral infection), called the post-transcriptional gene silencing (PTGS) pathway (Fire *et al.*, 1998). When used as a defense mechanism, PTGS induces the cleavage of double-stranded RNA (dsRNA) and allows for translational inhibition of exogenous mRNA (Hamilton and Baulcombe, 1999). dsRNAs are cleaved into smaller molecules, small interfering RNAs (siRNAs), which are subsequently associated with RISC, leading to gene silencing by RNA interference (RNAi). This will be discussed in more detail in a later section.

miRNA function

MiRNAs exhibit temporal- and tissue-specific expression (Lagos-Quintana *et al.*, 2002; Lagos-Quintana *et al.*, 2003; Liu *et al.*, 2005; Mehler and Mattick, 2006; Schratt *et al.*, 2006). One of the first functions associated with miRNA was the temporal regulation of development (Lee *et al.*, 1993; Wightman *et al.*, 1993). Negative post-transcriptional regulation of lin-14 by the lin-4 miRNA is essential for the formation of a temporal gradient of LIN-14 protein to ensure correct transition between the larval stages in *C. elegans*. The second miRNA discovered, let-7, also proved to be a key driver in the temporal pattern of development of *C. elegans* (Abrahante *et al.*, 2003; Lin *et al.*, 2003; Grosshans *et al.*, 2005).

To date, it has been shown that miRNAs regulate the expression of at least 1/3 of all human genes, and these are known to play an important role in several biological processes, including cell cycle regulation, apoptosis, cell differentiation, and embryonic development, etc. (Ketting *et al.*, 2001; Wienholds *et al.*, 2003; Ambros, 2004; Bartel, 2004; Lee *et al.*, 2004; Wienholds and Plasterk, 2005). Deregulation of miRNA expression is often associated with human cancers (Volinia *et al.*, 2006; Lu *et al.*, 2008) and can induce activation of oncogenes or inactivation of tumor suppressor genes (Esquela-Kerscher and Slack, 2006). DICER-deficient mice die because they lose their stem cell pluripotency (Bernstein *et al.*, 2003). Experiments with mutant DICER-1 in *Drosophila* show that the miRNA pathway is critical for cell division and for the passage from the G1 phase to the S phase of the cell cycle (Hatfield *et al.*, 2005). There is also evidence of miRNA involvement in metabolism as well as in the regulation of apoptosis. In flies, the miRNA bantam accelerates proliferation and prevents apoptosis by regulation of a proapoptotic gene, *hid* (Brennecke *et al.*, 2003). In vertebrates, miR-375 is ex-

pressed in pancreatic islets and suppresses the secretion of insulin induced by glucose (Poy *et al.*, 2004).

miRNAs have also been shown to play an important role in myogenesis and cardiogenesis. miR-1 is conserved from worms to mammals and is highly expressed in human muscle, fly muscle and the mouse heart (Aboobaker *et al.*, 2005; Zhao *et al.*, 2005). Interestingly, knockdown of this miRNA in *Drosophila* does not affect the formation and function of muscles during the larval stages, but instead affects the formation of muscles during growth in the adult animal (Sokol and Ambros, 2005). These results clearly show the role of miRNAs not only during development but also for further growth and tissue maintenance.

The association between miRNA deregulation and the development of pathological states was first discovered through studies in the field of oncology. One of the initial findings that showed that miRNAs indeed play a role in the regulation of oncogenes came from studies in chronic lymphocytic leukemia (Calin *et al.*, 2002). These studies showed that several human miRNA transcription sites are located in genomic regions involved in cancers, such as regions of chromosomal breakpoints and fragile sites (Calin *et al.*, 2004). Further studies demonstrated that differential expression of miRNAs is associated with tumor formation (Michael *et al.*, 2003; Calin *et al.*, 2004, 2005; Lu *et al.*, 2005). In a few cases, a correlation between specific miRNA expression patterns and cell type could be found (Lu *et al.*, 2005). In addition, most miRNAs are found to be down-regulated in tumor tissue when compared with normal tissue, which may lead to loss of cell differentiation (Lu *et al.*, 2005).

Recent studies have demonstrated that some viruses encode miRNAs (Pfeffer *et al.*, 2004) and that in the Epstein-Barr virus (EBV), a member of the herpesvirus family, these miRNAs are encoded in intergenic regions at specific clusters (Edwards *et al.*, 2008; Feederle *et al.*, 2011). These virus-encoded miRNAs have been shown to regulate their own genes (Barth *et al.*, 2008; Umbach *et al.*, 2008), as well as genes involved in virus-cell interactions (Murphy *et al.*, 2008), leading to a modulation of the host immune system (Stern-Ginossar *et al.*, 2007). In this way, it has been demonstrated that the BHRF1 miRNA cluster plays an important role in the transition from the latent virus state by enhancing expansion of the virus reservoir and reducing the viral antigenic load (Feederle *et al.*, 2011). Therefore, these features have the potential to facilitate persistence of the virus in the infected host and can be used as new therapeutic targets for the treatment of some EBV-associated lymphomas (Feederle *et al.*, 2011).

To better understand the function of miRNAs, it is also important to know their regulatory targets (*i.e.*, the genes regulated by specific miRNAs). Because it has been estimated that each miRNA could regulate a large number of targets (Kim, 2005; Baek *et al.*, 2008), bioinformatic algorithms have become a powerful tool for identifying

miRNA-regulated genes and predicting gene function. Therefore, a large number of predictive algorithms are available, such as TargetScan (Lewis *et al.*, 2003), miRanda (John *et al.*, 2004), PicTar (Krek *et al.*, 2005), RNA22 (Miranda, *et al.*, 2006), PITA (Kertesz *et al.*, 2007), DIANA-microT (Maragkakis *et al.*, 2009) and Tarbase (Hsu *et al.*, 2011). The main algorithm used to predict miRNA:mRNA interactions involves pairing of the 5' region of the miRNA - a 2-8 nt region known as the 'seed region' - to the 3' untranslated region (3'-UTR) of the mRNA (Thomson *et al.*, 2011). However, evidence suggests that the miRNA seed region pairing is not always a reliable predictor of miRNA:mRNA interactions (Didiano and Hobert, 2006). Indeed, precision of these algorithms is estimated to be approximately 50% when tested against experimental-proven miRNA targets (Alexiou *et al.*, 2009). Therefore, it is highly suggested that additional experiments should be performed to validate potential miRNA targets. These may include, but are not limited to, reporter gene assays, evaluation of miRNA and target mRNA co-expression (*e.g.*, northern blotting, qPCR or *in situ* hybridization) and assessment of miRNA effects on target protein expression (*e.g.*, ELISA, western blotting, immunohistochemistry) (Kertesz *et al.*, 2007; Kuhn, *et al.*, 2008; Nuovo, 2010; Thomson *et al.*, 2011 Hébert and Nelson, 2012; Vergoulis *et al.*, 2012).

Small Interfering RNAs and RNA Interference

RNAi is frequently used as a technique to promote effective and specific post-transcriptional gene silencing through the administration of double-stranded RNAs (dsRNAs). Although the phenomenon was first observed in plants and fungi, the clear triggering mechanism was originally reported in the nematode *C. elegans* (Fire *et al.*, 1998). In this work, the authors observed that after injecting long dsRNA molecules into the worm's gonad, the matching target mRNA was destroyed and a corresponding phenotypical change could be subsequently observed (Fire *et al.*, 1998).

After the initial description, RNAi was shown to be functional in nearly all eukaryotic species tested so far. Indeed, RNAi has been shown to be widely present, from viruses, unicellular organisms, fungi, plants and other animals. The technology promoted a revolution in molecular biology and medical sciences because it can be used to identify gene function or to silence essential genes present in a pathogen. The impact of RNAi is such that less than a decade after the seminal report, the discoverers were awarded the Nobel Prize. Investors also noted the immense potential behind this technique. As a result, several biotechnology start-ups emerged, devoted to the development of RNAi-based therapies (Check, 2004; Bonetta, 2007; Osborne, 2007).

RNAi can be triggered by two main types of double stranded RNA molecules. The first class encompasses long

molecules, approximately 300-800 base pairs (bp) in length, which may be produced by several processes, such as: i) RT-PCR followed by *in vitro* transcription (Goto *et al.*, 2003), ii) expression from a cDNA cloned in special vectors (Kamath *et al.*, 2001) or iii) a transgenic cassette (Chuang and Meyerowitz, 2000). These long dsRNAs are the molecules of choice when using the technology in non-mammalian models. Because dsRNAs longer than 30 bp promote lethal effects in mammalian cells, 21nt RNA duplexes, known as siRNAs, are the molecule of choice for use in mammals (Elbashir *et al.*, 2001). siRNAs can also be used in non-mammalian cells, but this molecule must be designed for the target gene and its functionality must first be tested *in vitro*.

RNAi can be used to create genetically modified animals in an attempt to recapitulate the null phenotype. Moreover, hypomorphic animals, *i.e.*, displaying intermediate levels of mRNA knockdown (from 0.1 to 99%), may also be generated via RNAi, because the efficiency of silencing can be controlled (Khvorova *et al.*, 2003, Schwarz *et al.*, 2003). Such genetic constructions, presenting intermediary phenotypes, may be of great biological value when the null animal is not viable (Baker *et al.*, 2004).

RNAi is frequently used as a strategy to identify gene function, but there are many other possibilities: i) to combat of several classes of pathogens (viruses, Palliser *et al.*, 2006; bacterial diseases, Escobar *et al.*, 2001; parasites, Pereira *et al.*, 2008), ii) to generate plants and animals of interest (Minton, 2004; Peng *et al.*, 2006) and iii) to control genetic diseases and tumors (Ptasznik *et al.*, 2004; Raoul *et al.*, 2005). All these new developments have recently led to the first published human clinical trials, with very promising results (Koldehoff *et al.*, 2007; Koldehoff and Elmagacali, 2009; Davis *et al.*, 2010; DeVincenzo *et al.*, 2010; Leachman *et al.*, 2010).

Future Directions

Progress in the area of ncRNAs seems to have occurred faster than in any major biological discipline in recent memory. The field has moved from virtual ignorance about an abundant class of regulatory molecules to a reasonably advanced understanding of the mechanisms of miRNA biogenesis and an emerging consensus about the numbers of miRNAs and their targets in several species, including humans. Recently, miRNAs have been used as a biomarker for several diseases. This is one of the most promising approaches in the use of these molecules (Zho and Wang, 2010; Cheng *et al.*, 2011; Ohyashiki *et al.*, 2011).

RNAi has promoted an enormous advancement in the field of molecular biology in the past decade. This technique allows a fast, cost-effective and simple alternative to promote down-regulation of virtually any gene from many species. RNAi-based drugs constitute the next big gamble of pharmaceutical companies for two main reasons: i) the

promise of being highly specific, because RNAi relies on total sequence complementarity, and ii) the fact that the associated pharmacodynamics may not be problematic, because RNA is a biological molecule. Therefore, it is very likely that RNAi may lead to innovative medical treatments in the near future.

Acknowledgments

Dr. Iscia Lopes-Cendes is supported by grants from FAPESP, FAPESP-CEPID (BRAINN), CNPq and EpimiRNA International Project.

References

- Aboobaker AA, Tomancak P, Patel N, Rubin GM and Lai EC (2005) *Drosophila* microRNAs exhibit diverse spatial expression patterns during embryonic development. *Proc Natl Acad Sci USA* 102:18017-18022.
- Abrahante JE, Daul AL, Li M, Volk ML, Tennesen JM, Miller EA and Rougvie AE (2003) The *Caenorhabditis elegans* hunchback-like gene *lin-57/hbl-1* controls developmental time and is regulated by microRNAs. *Dev Cell* 4:625-637.
- Alexiou P, Maragkakis M, Papadopoulos GL, Reczko M and Hatzigeorgiou AG (2009) Lost in translation: An assessment and perspective for computational microRNA target identification *Bioinformatics* 25:3049-3055.
- Ambros V (2001) microRNAs: Tiny regulators with great potential. *Cell* 107:823-826.
- Ambros V (2004) The functions of animal microRNAs. *Nature* 431:350-355.
- Ambros V, Bartel B, Bartel DP, Burge CB, Carrington JC, Chen X, Dreyfuss G, Eddy SR, Griffiths-Jones S, Marshall M, *et al.* (2003) A uniform system for microRNA annotation. *RNA* 9:277-279.
- Aravin AA, Lagos-Quintana M, Yalcin A, Zavolan M, Marks D, Snyder B, Gaasterland T, Meyer J and Tuschl T (2003) The small RNA profile during *Drosophila melanogaster* development. *Dev Cell* 5:337-350.
- Baek D, Villen J, Shin C, Camargo FD, Gygi SP and Bartel DP (2008) The impact of microRNAs on protein output. *Nature* 455:64-71.
- Baker DJ, Jeganathan KB, Cameron JD, Thompson M, Juneja S, Kopecka A, Kumar R, Jenkins RB, de Groen PC, Roche P, *et al.* (2004) BubR1 insufficiency causes early onset of aging-associated phenotypes and infertility in mice. *Nat Genet* 36:744-749.
- Bartel DP (2004) MicroRNAs: Genomics, biogenesis, mechanism and functions. *Cell* 23:281-297.
- Barth S, Pfuhl T, Mamiani A, Ehses C, Roemer K, Kremmer E, Jäker C, Höck J, Meister G and Grässer FA (2008) Epstein-Barr virus-encoded microRNA miR-BART2 down-regulates the viral DNA polymerase BALF5. *Nucleic Acids Res* 36:666-675.
- Bernstein E, Caudy AA, Hammond SM and Hannon GJ (2001) Role for a bidentate ribonuclease in the initiation step of RNA interference. *Nature* 409:363-366.
- Bernstein E, Kim SY, Carmell MA, Murchison EP, Alcorn H, Li MZ, Mills AA, Elledge SJ, Anderson KV and Hannon GJ (2003) Dicer is essential for mouse development. *Nat Genet* 35:215-217.

- Blevins T, Rajeswaran R, Shivaprasad PV, Beknazariants D, Si-Ammour A, Park HS, Vazquez F, Robertson D, Meins Jr F, Hohn T, *et al.* (2006) Four plant Dicers mediate viral small RNA biogenesis and DNA virus induced silencing. *Nucleic Acids Res* 34:6233-6246.
- Bonetta L (2007) Three researchers developing therapies based on RNA interference talk about their experiences leaving academia for biotech companies. *Biotechniques* 42:10-11.
- Brennecke J, Hipfner DR, Stark A, Russell RB and Cohen SM (2003) *bantam* encodes a developmentally regulated micro-RNA that controls cell proliferation and regulates the proapoptotic gene *hid* in *Drosophila*. *Cell* 113:25-36.
- Cai X, Hagedorn C and Cullen B (2004) Human microRNAs are processed from capped, polyadenylated transcripts that can also function as mRNAs. *RNA* 10:1957-1966.
- Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, Aldler H, Rattan S, Keating M, Rai K, *et al.* (2002) Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. *Proc Natl Acad Sci USA* 99:15524-15529.
- Calin GA, Liu CG, Sevignani C, Ferracin M, Felli N, Dumitru CD, Shimizu M, Cimmino A, Zupo S, Dono M, *et al.* (2004) MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. *Proc Natl Acad Sci USA* 101:11755-11760.
- Calin GA, Ferracin M, Cimmino A, Di Leva G, Shimizu M, Wojcik SE, Iorio MV, Visone R, Sever NI, Fabbri M, *et al.* (2005) A microRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. *N Engl J Med* 353:1793-1801.
- Cannell IG, Kong YW and Bushell M (2008) How do microRNAs regulate gene expression? *Biochem Soc Trans* 36:1224-1231.
- Check E (2004) RNA therapy beckons as firms prepare for clinical trials. *Nature* 429:792.
- Cheng H, Zang L, Cogdell DE, Zheng H, Schetter AJ, Nykter M, Harris CC, Chen K, Hamilton SR and Zhang W (2011) Circulating plasma miR-141 is a novel biomarker for metastatic colon cancer and predicts poor prognosis. *PLoS One* 6:e17745.
- Chuang CF and Meyerowitz EM (2000) Specific and heritable genetic interference by double-stranded RNA in *Arabidopsis thaliana*. *Proc Natl Acad Sci USA* 97:4985-4990.
- Collins FS, Patrinos A, Jordan E, Chakravarti A, Gesteland R and Walters L (1998) New goals for the U.S. Human Genome Project: 1998-2003. *Science* 282:682-689.
- Crick FH (1958) On protein synthesis. *Symp Soc Exp Biol* 12:138-163.
- Davis ME, Zuckerman JE, Choi CH, Seligson D, Tolcher A, Alabi CA, Yen Y, Heidel JD and Ribas A (2010) Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. *Nature* 464:1067-1070.
- Deleris A, Gallego-Bartolome J, Bao J, Kasschau KD, Carrington JC and Voinnet O (2006) Hierarchical action and inhibition of plant Dicer-like proteins in antiviral defense. *Science* 303:68-71.
- DeVincenzo J, Lambkin-Williams R, Wilkinson T, Cehelskyd J, Nochur S, Walsh E, Meyersd R, Gollob J and Vaishnav A (2010) A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus *Proc Natl Acad Sci USA* 107:8800-8805.
- Didiano D and Hobert (2006) Perfect seed pairing is not a generally reliable predictor for miRNA-target interactions. *Nat Struct Mol Biol* 13:849-851.
- Dieci G, Preti M and Montanini B (2009) Eukaryotic snoRNAs: A paradigm for gene expression flexibility. *Genomics* 94:83-88.
- Edwards RH, Marquitz AR and Raab-Traub N (2008) Epstein-Barr Virus BART microRNAs are produced from a large intron prior to splicing. *J Virol* 82:9094-9106.
- Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K and Tuschl T (2001) Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. *Nature* 411:494-498.
- Escobar MA, Civerolo EL, Summerfelt KR and Dandekar AM (2001) RNAi-mediated oncogene silencing confers resistance to crown gall tumorigenesis. *Proc Natl Acad Sci USA* 98:13437-13442.
- Esquela-Kerscher A and Slack FJ (2006) Oncomirs - microRNAs with a role in cancer. *Nat Rev Cancer* 6:259-269.
- Feederle R, Linnstaedt SD, Bannert H, Lips H, Bencun M, Cullen BR and Delecluse HJ (2011) A viral microRNA cluster strongly potentiates the transforming properties of a human herpesvirus. *PLoS Pathog* 7:e1001294.
- Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE and Mello CC (1998) Potent and specific genetic interference by double-stranded RNA in *Caenorhabditis elegans*. *Nature* 391:806-811.
- Gavazzo P, Vassalli M, Costa D and Pagano A (2013) Novel ncRNAs transcribed by Pol III and elucidation of their functional relevance by biophysical approaches. *Front Cell Neurosci* 7:203-215.
- Ghildiyal M and Zamore PD (2009) Small silencing RNAs: An expanding universe. *Nat Rev Genet* 10:94-108.
- Goto A, Blandin S, Royet J, Reichhart JM and Levashina EA (2003) Silencing of Toll pathway components by direct injection of double-stranded RNA into *Drosophila* adult flies. *Nucleic Acids Res* 31:6619-6623.
- Grosshans H, Johnson T, Reinert KL, Gerstein M and Slack FJ (2005) The temporal patterning microRNA let-7 regulates several transcription factors at the larval to adult transition in *C. elegans*. *Dev Cell* 8:321-330.
- Hamilton AJ and Baulcombe DC (1999) A species of small antisense RNA in posttranscriptional genesilencing in plants. *Science* 286:950-952.
- Han J, Lee Y, Yeom KH, Nam JW, Heo I, Rhee JK, Sohn SY, Cho Y, Zhang BT and Kim VN (2006) Molecular basis for the recognition of primary microRNAs by the Drosha-DGCR8 complex. *Cell* 125:887-901.
- Hatfield SD, Shcherbata HR, Fischer KA, Nakahara K, Carthew RW and Ruohola-Baker H (2005) Stem cell division is regulated by the microRNA pathway. *Nature* 435:974-978.
- Hébert SS and Nelson PT (2012) Studying microRNAs in the brain: Technical lessons learned from the first ten years. *Exp Neurol* 235:397-401.
- Hsu SD, Lin FM, Wu WY, Liang C, Huang WC, Chan WL, Tsai WT, Chen GZ, Lee CJ, Chiu CM, *et al.* (2011) miRTarBase: A database curates experimentally validated microRNA-target interactions. *Nucleic Acids Res* 39:D163-169.
- Hüttenhofer A, Schattner P and Polacek N (2005) Non-coding RNAs: Hope or hype? *Trends Genet* 21:289-297.

- Hutvagner G, McLachlan J, Pasquinelli AE, Bálint E, Tuschl T and Zamore PD (2001) A cellular function for the RNA-interference enzyme Dicer in the maturation of the let-7 small temporal RNA. *Science* 293:834-838.
- John B, Enright AJ, Aravin A, Tuschl T, Sander C and Marks DS (2004) Human microRNA targets. *PLoS Biol* 2:e363.
- Josse T, Teyssset L, Todeschini AL, Sidor CM, Anxolabéhère D and Ronsseray S (2007) Telomeric trans-silencing: An epigenetic repression combining RNA silencing and heterochromatin formation. *PLoS Genet* 3:1633-1643.
- Kamath RS, Martinez-Campos M, Zipperlen P, Fraser AG and Ahringer J (2001) Effectiveness of specific RNA-mediated interference through ingested double-stranded RNA in *Caenorhabditis elegans*. *Genome Biol* 2:RESEARCH0002.
- Kertesz M, Iovino N, Unnerstall U, Gaul U and Segal E (2007) The role of site accessibility in microRNA target recognition. *Nat Genet* 39:1278-1284.
- Ketting RF, Fischer SE, Bernstein E, Sijen T, Hannon GJ and Plasterk RH (2001) Dicer functions in RNA interference and in synthesis of small RNA involved in developmental timing in *C. elegans*. *Genes Dev* 15:2654-2659.
- Khorova A, Reynolds A and Jayasena SD (2003) Functional siRNAs and miRNAs exhibit strand bias. *Cell* 115:209-216.
- Kim VN (2005) MicroRNA biogenesis: Coordinated cropping and dicing. *Nat Rev Mol Cell Biol* 6:376-385.
- Kim YK and Kim VN (2007) Processing of intronic microRNAs. *EMBO J* 26:775-783.
- Koldehoff M and Elmaagacli AH (2009) Therapeutic targeting of gene expression by siRNAs directed against BCR-ABL transcripts in a patient with imatinib-resistant chronic myeloid leukemia. *Methods Mol Biol* 487:451-466.
- Koldehoff M, Steckel NK, Beelen DW and Elmaagacli AH (2007) Therapeutic application of small interfering RNA directed against bcr-abl transcripts to a patient with imatinib-resistant chronic myeloid leukaemia. *Clin Exp Med* 7:47-55.
- Krek A, Grün D, Poy MN, Wolf R, Rosenberg L, Epstein EJ, MacMenamin P, da Piedade I, Gunsalus KC, Stoffel M, *et al.* (2005) Combinatorial microRNA target predictions *Nat Genet* 37:495-500.
- Kuhn DE, Martin MM, Feldman DS, Terry Jr AV, Nuovo GJ and Elton TS (2008) Experimental validation of miRNA targets. *Methods* 44:47-54.
- Lagos-Quintana M, Rauhut R, Lendeckel W and Tuschl T (2001) Identification of novel genes coding for small expressed RNAs. *Science* 294:853-858.
- Lagos-Quintana M, Rauhut R, Yalcin A, Meyer J, Lendeckel W and Tuschl T (2002) Identification of tissue-specific microRNAs from mouse. *Curr Biol* 12:735-739.
- Lagos-Quintana M, Rauhut R, Meyer J, Borkhardt A and Tuschl T (2003) New microRNAs from mouse and human. *RNA* 9:175-179.
- Lai EC, Tomancak P, Williams RW and Rubin GM (2003) Computational identification of *Drosophila* microRNA genes. *Genome Biol* 4:R42.
- Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J, Devon K, Dewar K, Doyle M, FitzHugh W, *et al.* (2001) Initial sequencing and analysis of the human genome. *Nature* 409:860-921.
- Lau NC, Lim LP, Weinstein EG and Bartel DP (2001) An abundant class of tiny RNAs with probable regulatory roles in *Caenorhabditis elegans*. *Science* 294:858-862.
- Leachman SA, Hickerson RP, Schwartz ME, Bullough EE, Hutcherson SL, Boucher KM, Hansen CD, Eliason MJ, Srivatsa GS, Kornbrust DJ, *et al.* (2009) First-in-human mutation-targeted siRNA phase Ib trial of an inherited skin disorder. *Mol Ther* 18:442-446.
- Lee RC, Feinbaum RL and Ambros V (1993) The *C. elegans* heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. *Cell* 75:843-54.
- Lee Y, Jeon K, Lee JT, Kim S and Kim VN (2002) MicroRNA maturation: Stepwise processing and subcellular localization. *EMBO J* 21:4663-4670.
- Lee Y, Ahn C, Han J, Choi H, Kim J, Yim J, Lee J, Provost P, Rådmark O, Kim S, *et al.* (2003) The nuclear RNase III Drosha initiates microRNA processing. *Nature* 425:415-419.
- Lee YS, Nakahara K, Pham JW, Kim K, He Z, Sontheimer EJ and Carthew RW (2004) Distinct roles for *Drosophila* Dicer-1 and Dicer-2 in the siRNA/miRNA silencing pathways. *Cell* 117:69-81.
- Lewis BP, Shih I, Jones-Rhoades MW, Bartel DP and Burge CB (2003) Prediction of mammalian microRNA targets. *Cell* 115:787-798.
- Lin SY, Johnson SM, Abraham M, Vella MC, Pasquinelli A, Gamberi C, Gottlieb E and Slack FJ (2003) The *C. elegans* hunchback homolog, hbl-1, controls temporal patterning and is a probable microRNA target. *Dev Cell* 4:639-650.
- Liu J, Valencia-Sanchez MA, Hannon GJ and Parker R (2005) MicroRNA-dependent localization of targeted mRNAs to mammalian P-bodies. *Nat Cell Biol* 7:719-723.
- Lu Z, Liu M, Stribinskis V, Klinge CM, Ramos KS, Colburn NH and Li Y (2008) MicroRNA-21 promotes cell transformation by targeting the programmed cell death 4 gene. *Oncogene* 31:4373-4379.
- Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, *et al.* (2005) MicroRNA expression profiles classify human cancers. *Nature* 435:834-838.
- Lund E, Guttinger S, Calado A, Dahlberg JE and Kutay U (2004) Nuclear export of microRNA precursors. *Science* 303:95-98.
- Malone C and Hannon G (2009) Small RNAs as guardians of the genome. *Cell* 136:656-668.
- Maragkakis M, Alexiou P, Papadopoulos GL, Reczko M, Dalmagas T, Giannopoulos G, Goumas G, Koukis E, Kourtis K, Simossis VA, *et al.* (2009) Accurate microRNA target prediction correlates with protein repression levels. *BMC Bioinformatics* 10:e295.
- Matera AG, Terns RM and Terns MP (2007) Non-coding RNAs: Lessons from the small nuclear and small nucleolar RNAs. *Nat Rev Mol Cell Biol* 8:209-220.
- Mattick JS and Makunin IV (2005) Small regulatory RNAs in mammals. *Hum Mol Genet* 14(Spec No 1):R121-132.
- Megosh HB, Cox DN, Campbell C and Lin H (2006) The role of PIWI and the miRNA machinery in *Drosophila* germline determination. *Curr Biol* 16:1884-1894.
- Mehler MF and Mattick JS (2006) Non-coding RNAs in the nervous system. *J Physiol* 575:333-341.
- Michael MZ, O'Connor SM, van Holst Pellekaan NG, Young GP and James RJ (2003) Reduced accumulation of specific microRNAs in colorectal neoplasia. *Mol Cancer Res* 1:882-891.

- Minton K (2004) In the news: Allergen-free cats (Research Highlight). *Nat Rev Immunol* 4:926.
- Miranda KC, Huynh T, Tay Y, Ang YS, Tam WL, Thomson AM, Lim B and Rigoutsos I (2006) A pattern-based method for the identification of microRNA binding sites and their corresponding heteroduplexes *Cell* 126:1203-1217.
- Moss EG and Tang L (2003) Conservation of the heterochronic regulator Lin-28, its developmental expression and microRNA complementary sites. *Dev Biol* 258:432-442.
- Murphy E, Vanicek J, Robins H, Shenk T and Levine AJ (2008) Suppression of immediate-early viral gene expression by herpesvirus-coded microRNAs: Implications for latency. *Proc Natl Acad Sci USA* 105:5453-5458.
- Nuovo GJ (2010) *In situ* detection of microRNAs in paraffin embedded, formalin fixed tissues and the co-localization of their putative targets. *Methods* 52:307-315.
- Ohyashiki K, Umezu T, Yoshisawa S-I, Ito Y, Ohyashiki M, Kawashima H, Tanaka M, Kuroda M and Ohyashiki JH (2011) Clinical impact of down-regulated plasma levels of miR-92a levels in non-Hodgkins lymphoma. *PLOS One* 2:e16408.
- Okamura K, Hagen JW, Duan H, Tyler DM and Lai EC (2007) The mirtron pathway generates microRNA-class regulatory RNAs in *Drosophila*. *Cell* 130:1-12.
- Osborne R (2007) Companies jostle for lead in RNAi, despite uncertainties. *Nat Biotechnol* 25:1191-1192.
- Palliser D, Chowdhury D, Wang QY, Lee SJ, Bronson RT, Knipe DM and Lieberman J (2006) An siRNA-based microbicide protects mice from lethal herpes simplex virus 2 infection. *Nature* 439:89-94.
- Pasquinelli AE, Reinhart BJ, Slack F, Martindale MQ, Kuroda MI, Maller B, Hayward DC, Ball EE, Degnan B, Müller P, *et al.* (2000) Conservation of the sequence and temporal expression of let-7 heterochronic regulatory RNA. *Nature* 408:86-89.
- Peng S, York JP and Zhang P (2006) A transgenic approach for RNA interference-based genetic screening in mice. *Proc Natl Acad Sci USA* 103:2252-2256.
- Pereira TC, Pascoal VD, Marchesini RB, Maia IG, Magalhães LA, Zanotti-Magalhães EM and Lopes-Cendes I (2008) *Schistosoma mansoni*: Evaluation of an RNAi-based treatment targeting HGPRTase gene. *Exp Parasitol* 118:619-623.
- Peters J and Robson JE (2008) Imprinted noncoding RNAs. *Mamm Genome* 19:493-502.
- Pfeffer S, Zavolan M, Grässer FA, Chien M, Russo JJ, Ju J, John B, Enright AJ, Marks D, Sander C and Tuschl T (2004) Identification of virus-encoded microRNAs. *Science* 304:734-736.
- Poy MN, Eliasson L, Krutzfeldt J, Kuwajima S, Ma X, Macdonald PE, Pfeffer S, Tuschl T, Rajewsky N, Rorsman P, *et al.* (2004) A pancreatic islet-specific microRNA regulates insulin secretion. *Nature* 432:226-230.
- Ptasznik A, Nakata Y, Kalota A, Emerson SG and Gewirtz AM (2004) Short interfering RNA (siRNA) targeting the Lyn kinase induces apoptosis in primary, and drug-resistant, BCR-ABL1(+) leukemia cells. *Nat Med* 10:1187-1189.
- Raoul C, Abbas-Terki T, Bensadoun JC, Guillot S, Haase G, Szulc J, Henderson CE and Aebischer P (2005) Lentiviral-mediated silencing of SOD1 through RNA interference retards disease onset and progression in a mouse model of ALS. *Nat Med* 11:423-428.
- Reinhart BJ, Slack FJ, Basson M, Pasquinelli AE, Bettinger JC, Rougvie AE, Horvitz HR and Ruvkun G (2000) The 21-nucleotide let-7 RNA regulates developmental timing in *Caenorhabditis elegans*. *Nature* 403:901-906.
- Rodriguez A, Griffith-Jones S, Ashurst JL and Bradley A (2004) Identification of mammalian microRNA host genes and transcription units. *Genome Res* 14:1902-1910.
- Ruby JG, Jan CH and Bartel DP (2007) Intronic microRNA precursors that bypass Drosha processing. *Nature* 448:83-86.
- Ruvkun G and Giusto J (1989) The *Caenorhabditis elegans* heterochronic gene lin-14 encodes a nuclear protein that forms a temporal developmental switch. *Nature* 338:313-319.
- Schratt GM, Tuebing F, Nigh EA, Kane CG, Sabatini ME, Kiebler M and Greenberg ME (2006) A brain-specific microRNA regulates dendritic spine development. *Nature* 439:283-289.
- Schwarz DS, Hutvagner G, Du T, Xu Z, Aronin N and Zamore PD (2003) Asymmetry in the assembly of the RNAi enzyme complex. *Cell* 115:199-208.
- Shibata S, Sasaki M, Miki T, Shimamoto A, Furuichi Y, Katahira J and Yoneda Y (2006) Exportin-5 orthologues are functionally divergent among species. *Nucleic Acids Res* 34:4711-4721.
- Sokol NS and Ambros V (2005) Mesodermally expressed *Drosophila* microRNA-1 is regulated by Twist and is required in muscles during larval growth. *Genes Dev* 19:2343-2354.
- Stern-Ginossar N, Elefant N, Zimmermann A, Wolf DG, Saleh N, Biton M, Horwitz E, Prokocimer Z, Prichard M, Hahn G, *et al.* (2007) Host immune system gene targeting by a viral miRNA. *Science* 317:376-381.
- Taft RJ, Glazov EA, Lassmann T, Hayashizaki Y, Carninci P and Mattick JS (2009) Small RNAs derived from snoRNAs. *RNA* 15:1233-1240.
- Tazi J, Bakkour N and Stamm S (2009) Alternative splicing and disease. *Biochim Biophys Acta* 1792:14-26.
- Theurkauf WE, Klattenhoff C, Bratu DP, McGinnis-Schultz N, Koppetsch BS and Cook HA (2006) rasiRNAs, DNA damage, and embryonic axis specification. *Cold Spring Harb Symp Quant Biol* 71:171-180.
- Thomson DW, Bracken CP and Goodall GJ (2011) Experimental strategies for microRNA target identification. *Nucleic Acids Res* 39:6845-6853.
- Umbach JL, Kramer MF, Jurak I, Karnowski HW, Coen DM and Cullen BR (2008) MicroRNAs expressed by herpes simplex virus 1 during latent infection regulate viral mRNAs. *Nature* 454:780-783.
- Valadkhan S (2005) snRNAs as the catalysts of pre-mRNA splicing. *Curr Opin Chem Biol* 9:603-608.
- Vergoulis T, Vlachos IS, Alexiou P, Georgakilas G, Maragkakis M, Reczko M, Gerangelos S, Koziris N, Dalamagas T and Hatzigeorgiou AG (2012) TarBase 6.0: Capturing the exponential growth of miRNA targets with experimental support. *Nucleic Acids Res* 40:D222-229.
- Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, *et al.* (2006) A microRNA expression signature of human solid tumors defines cancer gene targets. *Proc Natl Acad Sci USA* 103:2257-2261.
- Wang Y, Medvid R, Melton C, Jaenisch R and Blalock R (2007) DGCR8 is essential for microRNA biogenesis and silencing of embryonic stem cell self-renewal. *Nat Genet* 39:380-385.

- Wienholds E and Plasterk RH (2005) MicroRNA function in animal development. *FEBS Lett* 597:5911-5922.
- Wienholds E, Koudijs MJ, van Eeden FJ, Cuppen E and Plasterk RH (2003) The microRNA-producing enzyme Dicer1 is essential for zebrafish development. *Nat Genet* 35:217-218.
- Wightman B, Ha I and Ruvkun G (1993) Posttranscriptional regulation of the heterochronic gene *lin-14* by *lin-4* mediates temporal pattern formation in *C. elegans*. *Cell* 75:855-862.
- Xie Z, Allen E, Wilken A and Carrington JC (2005) Dicer-like 4 functions in trans-acting small interfering RNA biogenesis and vegetative phase change in *Arabidopsis thaliana*. *Proc Natl Acad Sci USA* 102:12984-12989.
- Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M, Stephens RM, Okamoto A, Yokota J, Tanaka T, *et al.* (2006) Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. *Cancer Cell* 9:189-198.
- Yi R, Qin Y, Macara IG and Cullen BR (2003) Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs. *Genes Dev* 17:3011-3016.
- Zhao Y, Samal E and Srivastava D (2005) Serum response factor regulates a muscle-specific microRNA that targets *Hand2* during cardiogenesis. *Nature* 436:214-220.
- Zho S-L and Wang L-D (2010) Circulating microRNAs: Novel biomarkers for esophageal cancer. *World J Gastroenterol* 16:2348-2354.

License information: This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.